Pediatric high risk neuroblastoma with autologous stem cell transplant – 20 years of experience-Reference-Cited by-同舟云学术

Pediatric high risk neuroblastoma with autologous stem cell transplant – 20 years of experience

Published:2021-12 Issue:4 Volume:8 Page:253-257
ISSN:2352-6467
Container-title:International Journal of Pediatrics and Adolescent Medicine
language:en
Short-container-title:International Journal of Pediatrics and Adolescent Medicine

Author:

Khan Saadiya^ORCID,AlSayyad Khulood^ORCID,Siddiqui Khawar,AlAnazi Awatif,AlSeraihy Amal,AlAhmari Ali,ElSolh Hassan,Ghemlas Ibrahim,AlSaedi Hawazen,AlJefri Abdullah,Ali Afshan,AlFawaz Ibrahim^ORCID,AlKofide Amani,Ayas Mouhab

Publisher

Elsevier BV

Subject

Pediatrics, Perinatology and Child Health

Reference26 articles.

1. Neuroblastoma

2. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial;Kreissman;Lancet Oncol,2013

3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial;Ladenstein;Lancet Oncol,2017

4. The international neuroblastoma risk group (INRG) classification system: an INRG task force report;Cohn;J Clin Oncol,2009

5. Advances in risk classification and treatment strategies for neuroblastoma;Pinto;J Clin Oncol,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma;Journal of Personalized Medicine;2024-09-08

2. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation;BMC Cancer;2024-08-13

3. Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai;American Journal of Cancer Research;2024

4. MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment;Cancers;2022-09-12